GlaxoSmithKline Buys Maxinutrition From Darwin PE

Pharmaceutical giant GlaxoSmithKline has agreed to pay 162 million pounds ($255 million) for private equity-backed Maxinutrition Group Holdings. GlaxoSmithKline will acquire 100% of the shares, providing an exit for Darwin Private Equity. UK-based Maxinutrition manufactures protein-enhanced nutrition products. London-based Darwin Private Equity acquired Maxinutrition in 2007.